Terms: = Prostate cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Treatment
35 results:
1. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract] [Full Text] [Related]
2. Cardiac glycoside neriifolin exerts anti-cancer activity in prostate cancer cells by attenuating DNA damage repair through endoplasmic reticulum stress.
Zhao W; Li G; Zhang Q; Chen M; He L; Wu Z; Zhang Y; Fan M; Liang Y; Zhang W; Zeng F; Deng F
Biochem Pharmacol; 2023 Mar; 209():115453. PubMed ID: 36792037
[TBL] [Abstract] [Full Text] [Related]
3. Antioxidative, anti-inflammatory, and anticancer properties of the red biopigment extract from Monascus purpureus (MTCC 369).
Chaudhary V; Katyal P; Panwar H; Kaur J; Aluko RE; Puniya AK; Poonia AK
J Food Biochem; 2022 Sep; 46(9):e14249. PubMed ID: 35615960
[TBL] [Abstract] [Full Text] [Related]
4. Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol.
Khan MA; Singh D; Fatma H; Akhtar K; Arjmand F; Maurya S; Siddique HR
Drug Chem Toxicol; 2023 Mar; 46(2):380-391. PubMed ID: 35188013
[TBL] [Abstract] [Full Text] [Related]
5. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract] [Full Text] [Related]
6. treatment of Large Non-Muscle-Invasive Bladder cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
Raber M; Buchholz N; Vercesi A; Hendawi NA; Inneo V; Di Paola G; Tessa L; Gazzano G; Viglio A; Hasan IM
Urol Int; 2021; 105(3-4):298-303. PubMed ID: 33333529
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer Biomarker Development: National cancer Institute's Early Detection Research Network prostate cancer Collaborative Group Review.
Liss MA; Leach RJ; Sanda MG; Semmes OJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2454-2462. PubMed ID: 33093161
[TBL] [Abstract] [Full Text] [Related]
8. Androgens and Overall Survival in Patients With Metastatic Castration-resistant prostate cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract] [Full Text] [Related]
9.
Martínez-Rojo E; Cariño-Cortés R; Berumen LC; García-Alcocer G; Escobar-Cabrera J
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32102219
[No Abstract] [Full Text] [Related]
10. Leveraging Digital Data to Inform and Improve Quality cancer Care.
Hernandez-Boussard T; Blayney DW; Brooks JD
Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):816-822. PubMed ID: 32066619
[TBL] [Abstract] [Full Text] [Related]
11. A method to verify sections of arc during intrafraction portal dosimetry for prostate VMAT.
Bedford JL; Hanson IM
Phys Med Biol; 2019 Oct; 64(20):205009. PubMed ID: 31553964
[TBL] [Abstract] [Full Text] [Related]
12. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Ryan CJ; Dutta S; Kelly WK; Russell C; Small EJ; Morris MJ; Taplin ME; Halabi S;
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):66-73. PubMed ID: 31053766
[TBL] [Abstract] [Full Text] [Related]
13. Enhanced Susceptibility to 5-Fluorouracil in Human Colon cancer Cells by Silencing of GRP78.
Yun S; Han YS; Lee JH; Kim S; Lee SH
Anticancer Res; 2017 Jun; 37(6):2975-2984. PubMed ID: 28551635
[TBL] [Abstract] [Full Text] [Related]
14. Imaging practices and radiation doses from imaging in radiotherapy.
Siiskonen T; Kaijaluoto S; Florea T
Phys Med; 2017 Oct; 42():247-252. PubMed ID: 28351527
[TBL] [Abstract] [Full Text] [Related]
15. Prevalence of co-morbidities and evaluation of their monitoring in Korean patients with rheumatoid arthritis: comparison with the results of an international, cross-sectional study (COMORA).
Choi IA; Park SH; Cha HS; Park W; Kim HA; Yoo DH; Baek HJ; Lee SG; Lee YJ; Park YB; Shim SC; Hmamouchi I; Song YW
Int J Rheum Dis; 2018 Jul; 21(7):1414-1422. PubMed ID: 28261976
[TBL] [Abstract] [Full Text] [Related]
16. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment.
Bergius S; Torvinen S; Muhonen T; Roine RP; Sintonen H; Taari K
Scand J Urol; 2017 Feb; 51(1):13-19. PubMed ID: 27809631
[TBL] [Abstract] [Full Text] [Related]
17. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.
Barakat DJ; Zhang J; Barberi T; Denmeade SR; Friedman AD; Paz-Priel I
Oncogene; 2015 Nov; 34(48):5912-22. PubMed ID: 25772238
[TBL] [Abstract] [Full Text] [Related]
18. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
[TBL] [Abstract] [Full Text] [Related]
19. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy.
Firczuk M; Gabrysiak M; Barankiewicz J; Domagala A; Nowis D; Kujawa M; Jankowska-Steifer E; Wachowska M; Glodkowska-Mrowka E; Korsak B; Winiarska M; Golab J
Cell Death Dis; 2013 Jul; 4(7):e741. PubMed ID: 23887632
[TBL] [Abstract] [Full Text] [Related]
20. Indole-3-carbinol inhibits telomerase activity and gene expression in prostate cancer cell lines.
Adler S; Rashid G; Klein A
Anticancer Res; 2011 Nov; 31(11):3733-7. PubMed ID: 22110194
[TBL] [Abstract] [Full Text] [Related]
[Next]